Synopsis
Synopsis
0
API Suppliers
0
USDMF
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
NDC API
0
VMF
0
Listed Suppliers
0
API
0
FDF
0
FDF Dossiers
0
FDA Orange Book
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
EDQM
0
USP
0
JP
0
Others
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
0
News #PharmaBuzz
US Medicaid
NA
Annual Reports
NA
Finished Drug Prices
NA
1. 152811-62-6
2. Sb-207266
3. N-((1-butylpiperidin-4-yl)methyl)-3,4-dihydro-2h-[1,3]oxazino[3,2-a]indole-10-carboxamide
4. N-[(1-butylpiperidin-4-yl)methyl]-3,4-dihydro-2h-[1,3]oxazino[3,2-a]indole-10-carboxamide
5. Sb207256
6. 4uq3s81b25
7. Sb 207266
8. Piboserod,2h-(1,3)oxazino(3,2-a)indole-10-carboxamide, N-((1-butyl-4-piperidinyl)methyl)-3,4-dihydro-
9. N-[(1-butyl-4-piperidinyl)methyl]-3,4-dihydro-2h-[1,3]-oxazino[3,2-a]indole-10-carboxamide
10. Piboserod [inn]
11. Piboserod [inn:ban]
12. Serotonin 5-ht4 Receptor Antagonists
13. Unii-4uq3s81b25
14. Piboserod [mi]
15. Sb207266(piboserod)
16. Piboserod [who-dd]
17. Gtpl225
18. Schembl467339
19. Chembl356359
20. Bdbm85026
21. Dtxsid60165129
22. Bcp15982
23. Ex-a1189
24. Zinc1537633
25. Mfcd00923681
26. Pdsp1_001702
27. Pdsp2_001685
28. Akos015909931
29. Db04873
30. Fd10684
31. Sb 207266-a
32. Ncgc00250378-01
33. Ac-36094
34. As-82492
35. Bp166459
36. Hy-15574
37. Sb 207256
38. Ft-0722955
39. Q75884
40. Sb-207266, >=98% (hplc)
41. L000973
42. N-(1-butylpiperidine-4-ylmethyl)-1,2-(trimethyleneoxy)-1h-indole-3-carboxamide
43. 2h-(1,3)oxazino(3,2-a)indole-10-carboxamide, N-((1-butyl-4-piperidinyl)methyl)-3,4-dihydro-
44. N-((1-butyl-4-piperidyl)-methyl)-3,4-dihydro-2h-(1,3)oxazino(3,2-a)indole-10-carboxamide
45. N-((1-butyl-4-piperidyl)methyl)-3,4-dihydro-2h-(1,3)oxazino(3,2-a)indole-10-carboxamide
46. N-[(1-butyl-4-piperidinyl)methyl]-3,4-dihydro-2h-[1,3]-oxazino[3,2-alpha]indole-10-carboxamide
47. N-[(1-butyl4-piperidinyl)methyl]-3,4-dihydro-2h-[1,3]-oxazino[3,2-a]indole-10-carboxamide
48. N-[(1-butylpiperidin-4-yl)methyl]-2h,3h,4h-[1,3]oxazino[3,2-a]indole-10-carboxamide
Molecular Weight | 369.5 g/mol |
---|---|
Molecular Formula | C22H31N3O2 |
XLogP3 | 3.7 |
Hydrogen Bond Donor Count | 1 |
Hydrogen Bond Acceptor Count | 3 |
Rotatable Bond Count | 6 |
Exact Mass | 369.24162724 g/mol |
Monoisotopic Mass | 369.24162724 g/mol |
Topological Polar Surface Area | 46.5 Ų |
Heavy Atom Count | 27 |
Formal Charge | 0 |
Complexity | 492 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 0 |
Undefined Atom Stereocenter Count | 0 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 1 |
For the treatment of atrial fibrillation and irritable bowel syndrome (IBS).
GlaxoSmithKline was investigating piboserod, a 5HT4 antagonist, for the treatment of atrial fibrillation. Phase II trials were ongoing in March 2004, but by December of that year, development had been discontinued. Piboserod had previously being investigated for the treatment of irritable bowel syndrome (IBS), but development for this indication was terminated in 1999.
Piboserod appears to act as a specific antagonist of one of the receptors for 5-hydroxytryptamine, the 5-HT4 receptor. The 5-HT4 receptor antagonists are thought to antagonize both the ability of serotonin to sensitize the peristaltic reflex and 5-HT-induced defecation, at least in animal studies. As 5-HT4 receptors are present in human atrial cells and when stimulated may cause atrial arrhythmias, piboserod was under investigation in clinical trials for atrial fibrillation.
ABOUT THIS PAGE
LOOKING FOR A SUPPLIER?